Sara Dehbashi, MD
Neuromuscular Medicine · Philadelphia, PANPI 1265852206
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations.
Across 14 payments — averaging $61.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$150
- AbbVie$146
- AstraZeneca$134
- Akcea Therapeutics, Inc.$122
- Argenx US, Inc.$98
- Novartis$92
- plus $115 from 2 others
What the payments were for
- Food & beverage$856100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 1 | $150 |
| AbbVie | 4 | $146 |
| AstraZeneca | 1 | $134 |
| Akcea Therapeutics, Inc. | 1 | $122 |
| Argenx US, Inc. | 1 | $98 |
| Novartis | 1 | $92 |
| Johnson & Johnson | 3 | $60 |
| UCB, Inc. | 2 | $55 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neuromuscular medicine providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 82 | $1,617,831 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 65 | $1,276,566 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 95 | $1,176,282 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 59 | $772,212 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 37 | $516,403 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 21 | $393,529 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 19 | $321,778 |
| Mycophenolate Mofetil | 46 | $13,242 |
| Pyridostigmine Bromide | 25 | $3,224 |
| Duloxetine Hcl | 137 | $3,102 |
| Pregabalin | 87 | $2,699 |
| Gabapentin | 156 | $2,279 |
| Lidocaine | 19 | $2,086 |
| Amitriptyline Hcl | 122 | $926 |
| Sodium Chloride0.9 % Sodium Chloride | 59 | $442 |
Paid to pharmacies, not to this prescriber.
Other neuromuscular medicine in Philadelphia
- Paul McIntoshPhiladelphia$49K
- Hristelina IlievaPhiladelphia$5K
- Gema Giler-SacotoPhiladelphia$527
- Jessica YiPhiladelphia$340
- Rebecca HsuPhiladelphia$191
- Bradley TuckerPhiladelphia$112
- Michael BaerPhiladelphia$18
- Fang SunPittsburgh$2K
- Naaima MuftiEaston$629
- Connie TangAllentown$261
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.